UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
____________________
FORM 8-K
____________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
MIMEDX GROUP, INC.
(Exact name of registrant as specified in charter)
|
| | | | |
Florida | | | | 26-279552 |
(State
or other jurisdiction | | (Commission | | (IRS Employer |
of incorporation) | | file number) | | Identification No.) |
(Address of Principal Executive Offices) (Zip Code)
Registrant’s telephone number, including area code: (770) 651-9100 ____________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): |
| |
o | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
| |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
| |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
| |
o | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
| | | | |
Title of each class | | Trading Symbol(s) | | Name of each exchange on which registered |
None | | n/a | | n/a |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
2.02 Results of Operations and Financial Condition.
Item 7.01 Regulation FD Disclosure.
On March 17, 2020, MiMedx Group, Inc. (the “Company”) issued a press release announcing the filing of its annual report on Form 10-K for the fiscal year ended December 31, 2018, which includes the Company’s audited financial statements for the years ended December 31, 2018 and 2017, which the
Company had not previously filed, and for the year ended December 31, 2016, which the Company has restated. The press release also includes certain information regarding the Company’s results of operations for the fiscal year ended December 31, 2019. As noted in the press release, the Company plans to announce the date of its 2019 annual
meeting of shareholders after it files its annual report on Form 10-K for the fiscal year ended December 31, 2019. Under Securities and Exchange Commission rules, the Company cannot hold its 2019 annual meeting until audited financial statements for the fiscal year ended December 31, 2019 are available to shareholders. The foregoing information is furnished pursuant to Item 2.02,
“Results of Operations and Financial Condition,” and Item 7.01, “Regulation FD Disclosure.” Consequently, it is not deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section. It may only be incorporated by reference into another filing under the Exchange Act or Securities Act of 1933 if such subsequent filing specifically references this Form 8-K. All information in the press release speaks as of the date thereof, and the Company does not assume any obligation to update such information in the future, except as required by law.
Item
9.01 Exhibits
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report
to be signed on its behalf by the undersigned hereunto duly authorized.
|
| | |
| | MIMEDX GROUP, INC. |
| | |
| By: | |
| | Chief Executive Officer |
